Forepont Capital Partners — Full Portfolio
15 tracked investments · listed companies and verified rows first
Ansella Therapeutics develops novel vaginal formulations for women's health conditions using biomimetic materials science and biomedical engineering, focused on treating menopause, vaginal dryness, dyspareunia, vaginal mucositis, endometriosis, uterine fibroids, and vaginal infections.
BiotechFemTechMedical DevicesAustin, US
BCV Systems develops a mechatronic guidewire system using shape memory alloy actuators to optimize navigation during minimally invasive endovascular procedures for stroke treatment and other vascular interventions.
Deep TechHealthtechMedical DevicesParis, FR
Dr Raphaël Blanc(President)Jérôme Szewczyk(Researcher at the Institute of Intelligent Systems and Robotics ISIR, Professor at Sorbonne University)Jean-Baptiste Cazeneuve(CTO, Mechatronic Engineer)
BayBridgeDigital is a Salesforce consulting firm that helps retailers, healthcare, real estate, education, and hospitality companies with digital transformation through CRM implementation, data management, and cloud platform integration.
Data & InfrastructureEnterprise SoftwareSaaSNew York, US
Alain Attias(Founder)inGuy Jerusalmi(Executive Officer)ALAIN ATTIAS(Executive Officer)
BeCareLink builds AI-enhanced mobile platforms for remote neurological assessments, allowing patients to monitor their neurological health from home while helping clinicians and researchers track disease progression.
AI & Machine LearningDigital HealthHealthtech
Lawrence Rubin(Co-founder)Charisse D. Litchman(Co-founder)
BioSpeedia is a biotechnology company that develops and produces rapid lateral-flow diagnostic tests for infectious diseases, including tests for bacterial meningitis and SARS-CoV-2.
BiotechHealthtechMedical Devices
Evelyne Begaud(Co-founder & President)Yves Germani(Co-founder & Chief Scientific Officer)
Blackrock Neurotech develops a neurotechnology platform, including brain-computer interface systems, aimed at improving patient lives and treating neurological conditions.
BiotechDeep TechMedical Devices
Florian Solzbacher(Co-Founder & CSO)Marcus Gerhardt(Co-Founder & CEO)Thomas Thiele(CFO)
BoardChristian Angermayer(Co-Chairman)Tim Sievers(Co-Chairman)
Co-investors2050 CapitalCatalio Capital Management, LP
Exeliom Biosciences is a biotechnology company developing biotherapies, with work in areas such as inflammatory bowel disease (Crohn's and colitis).
BiotechDeep TechDigital HealthMedical DevicesParis, FR
Harry Sokol(Scientific Co-founder)
BiotechWilmington, US
Timothy Hirst(Executive Officer, Director)James Selkirk(Executive Officer)
Co-investorsKern Capital, LLCShearwater Capital
Co-investorsShearwater Capital
Co-investorsAphelion Capital
Precision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts.
Deep TechDigital HealthMedical Devices
Co-investorsB Capital GroupB4 CapitalDraper AssociatesSteadview Capital
HealthtechNew York, US
Benjamin Rapoport(President, Chief Science Officer)Michael Mager(Chief Executive Officer)Craig Mermel(President and Chief Product Officer)MIchael Kaswan(Chief Financial Officer)
BoardEric M. Attias(Director)Howard Morgan(Director)in
Co-investorsAlumni VenturesB Capital GroupBasecamp FundSCI VenturesSteadview Capital
Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline.
BiotechDeep TechMedical DevicesCampbell, US
Thomas James Oxley(Executive Officer, Director)Nicholas Opie(Director)inThomas Oxley(Founder)in
BoardRahul Sharma(Director)Alex Morgan(Director)inMartin Dieck(Director)
Co-investorsARCH Venture PartnersID8 InvestmentsKaleida CapitalKhosla VenturesBezos ExpeditionsIn-Q-Tel+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.